Roche’s H1 Report Looms Over a Wave of Regulatory and Clinical Advances
Published on 07/18/2026 at 19:03 | Redaktion boerse-global.de
Roche shares have barely stirred despite a cascade of pipeline updates over the past week, leaving investors to treat the 23 July half-year report as the real gauge of momentum. The stock closed at 323.90?GBP on Friday with a relative-strength index of 47.0, a neutral reading that underscores the market’s reluctance to price in the newsflow until the numbers land. At a market capitalisation of €354.23?billion, Europe’s largest healthcare company by value appears to be in a wait-and-see phase.
Two separate US Food and Drug Administration priority reviews now sit on Roche’s calendar. The first, for Tecentriq in combination with chemotherapy in colorectal cancer, was granted on the back of the Alliance?ATOMIC study, in which the regimen cut the risk of relapse or death by 50?% compared with standard care. The FDA is expected to decide by 9?October?2026. The second priority review covers Gazyva (also known as Gazyvaro) for primary membranous nephropathy, a rare kidney condition; that decision is due by November?2026. Meanwhile, earlier in July Roche announced that its KRAS?G12C inhibitor Divarasib had shown superiority over existing inhibitors in a phase?III lung?cancer trial, further strengthening the oncology pipeline.
In neurology, Roche presented fresh data on its Alzheimer’s antibody Trontinemab at the Alzheimer’s Association International Conference 2026. At a dose of 3.6?mg/kg, 92?% of participants achieved brain amyloid negativity after 28?weeks, a strong signal of plaque clearance. Phase?III studies – TRONTIER?1, TRONTIER?2 and the forthcoming PrevenTRON trial in early?stage patients – are underway or about to start. Safety data showed infusion reactions in 8.6?% of participants and anaemia in 3.7?%, with one death judged unrelated to the drug. If the amyloid results hold in the larger studies, Trontinemab could give Roche a foothold in one of the fastest?growing pharmaceutical segments.
Should investors sell immediately? Or is it worth buying Roche?
The diagnostics division has also been active. The FDA approved VENTANA PTEN (SP218), the first immunohistochemical companion test for prostate cancer, while in Europe Roche launched the cobas Hepatitis D Virus test – the first fully automated solution for detecting this severe form of viral hepatitis – and earned CE marking for a new blood test to identify tuberculosis infections. These launches reinforce a strategy of tying diagnostic tools more closely to therapeutic development.
Chief executive Thomas Schinecker and finance chief Alan Hippe will present the first?half results on 23?July. Preliminary figures showed currency?adjusted group sales up 7?% and core earnings ahead by 13?%, with diagnostics contributing 2?% growth. Investors will be watching how much the strong Swiss franc weighed on reported earnings and whether the pipeline milestones are beginning to translate into financial momentum. The FDA’s decisions on Tecentriq and Gazyva later this year will offer further clarity on how successfully Roche is broadening its oncology and rare?disease portfolios.
Ad
Roche Stock: New Analysis - 18 July
Fresh Roche information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
